USPTO serial 79306431
SKINVIVAID
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 30, 2022
- Examiner
- FLETCHER, TRACY L
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SKINVIVAID?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Genesis Specialist Care Holding UK Limited
GB
Other trademarks owned by Genesis Specialist Care Holding UK Limited
Genesis Specialist Care Holding UK Limited
GB
Other trademarks owned by Genesis Specialist Care Holding UK Limited
Genesis Specialist Care Holding UK Limited
GB
Other trademarks owned by Genesis Specialist Care Holding UK Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew S. Ehard
P.O. BOX 2910MINNEAPOLIS, MN 55402UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable computer software for assessing the severity of skin cancerization and damage for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; electronic publications, namely, downloadable magazines, books, newsletters, and articles in the field of medicine; electronic publications relating to medical matters, namely, downloadable magazines, books, newsletters, and articles in the field of medicine; digital downloadable questionnaires for medical assessments; downloadable computer software for assessing the severity of skin cancerization and damage for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services in the diagnosis, monitoring and treatment of medical and health conditions; downloadable computer software for assessing the severity of skin cancerization and damage for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services in the diagnosis, monitoring and treatment of skin conditions; downloadable customer relationship management (CRM) computer software for the management of the medical patient experience; computer software providing medical and health content, namely, downloadable educational computer software featuring medical instruction for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; computer software providing medical and health content relating to skin, namely, downloadable educational computer software featuring medical instruction for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; computer software for harmonised care management of medical patients, namely, downloadable computer software for enabling healthcare providers to view patient clinical data across multiple providers and enabling patients to view and download a complete, digital medical history for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; computer software for medical patient administration, namely, downloadable computer software for enabling healthcare providers to view patient clinical data across multiple providers and sites and enabling patients and healthcare providers to view and download a complete, digital medical history | ACTIVE | — |
| 042 | Software as a service (SaaS) services featuring software for assessing the severity of skin cancerization and damage for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; software as a service for the diagnosis, monitoring and treatment of medical and health conditions, namely, software as a service (SaaS) services featuring software for assessing the severity of skin cancerization and damage for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; software as a service for the diagnosis, monitoring and treatment of skin conditions, namely, software as a service (SaaS) services featuring software for assessing the severity of skin cancerization and damage for use in relation to pre-cancer treatment services, cancer treatment services, and radiation therapy services; software as a service (SaaS) services featuring customer relationship management (CRM) software for the management of the medical patient experience; software as a service (SaaS) services featuring software for providing medical and health content in the nature of enabling healthcare providers to view patient clinical data across multiple providers and sites and enabling patients and healthcare providers to view and download a complete, digital medical history; software as a service (SaaS) services featuring software for providing medical and health content relating to skin in the nature of enabling healthcare providers to view patient clinical data across multiple providers and sites and enabling patients and healthcare providers to view and download a complete, digital medical history; software as a service (SaaS) services featuring software for enabling healthcare providers to view patient clinical data across multiple providers and sites and enabling patients and healthcare providers to view and download a complete, digital medical history for harmonised care management of medical patients; software as a service (SaaS) services featuring medical patient administration software for enabling healthcare providers to view patient clinical data across multiple providers and sites and enabling patients and healthcare providers to view and download a complete, digital medical history | ACTIVE | — |
| 044 | Radiation oncology services; radiation therapy services; medical clinic services; medical treatment services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Genesis Specialist Care Holding UK Limited
- Other trademarks owned by Genesis Specialist Care Holding UK Limited
- Other trademarks owned by Genesis Specialist Care Holding UK Limited
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SKINVIVAID
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 26, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 28, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 7, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 7, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 30, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 16, 2022 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Sep 4, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 30, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 30, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 17, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 17, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 14, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 5, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 14, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 14, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 8, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 8, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 25, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 10, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 10, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 10, 2022 | ALIE | ASSIGNED TO LIE | — |
| May 10, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 10, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 10, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 19, 2022 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 16, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 16, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 16, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 15, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 15, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 15, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 5, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 14, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 14, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 12, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 11, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 7, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 16, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 11, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |